Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 365 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Hepatic Impairment Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT03902002

View directory record Official record

Conditions: Hepatic Impairment
Interventions: Omaveloxolone 50 mg capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Tustin, California • Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated May 29, 2025 · Synced May 21, 2026, 7:18 PM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems

NCT07486102

View directory record Official record

Conditions: Healthy, Hepatic Impairment
Interventions: BI 3000202; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated May 13, 2026 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide in Participants With Impaired Liver Function

NCT03940742

View directory record Official record

Conditions: Hepatic Insufficiency
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Tustin, California • Orlando, Florida • New Orleans, Louisiana

Source: ClinicalTrials.gov public record

Updated Mar 23, 2023 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 4 Interventional

A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions

NCT00144248

View directory record Official record

Conditions: HIV Infections, Hepatic Insufficiency
Interventions: nevirapine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older

Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 5
States / cities: Bakersfield, California • San Francisco, California • Albany, New York + 1 more

Source: ClinicalTrials.gov public record

Updated Nov 30, 2023 · Synced May 21, 2026, 7:18 PM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

NCT07324616

View directory record Official record

Conditions: Hepatic Impairment (HI)
Interventions: EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Mar 8, 2026 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Adults With or Without Liver Damage

NCT05976321

View directory record Official record

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: TAK-279; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older

Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Aug 28, 2024 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001

NCT06619054

View directory record Official record

Conditions: Healthy Adults, Hepatic Impairment
Interventions: KP-001; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 20 Years and older

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Oct 30, 2025 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

NCT02536911

View directory record Official record

Conditions: Gaucher Disease
Interventions: eliglustat; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • Knoxville, Tennessee

Source: ClinicalTrials.gov public record

Updated Feb 9, 2017 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

NCT06444204

View directory record Official record

Conditions: Hepatic Function Abnormal, Healthy Volunteers
Interventions: Rilzabrutinib; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jun 4, 2024 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

NCT06222892

View directory record Official record

Conditions: Cough
Interventions: Camlipixant; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Jan 6, 2026 · Synced May 21, 2026, 7:18 PM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

NCT06962332

View directory record Official record

Conditions: Hepatic Impairment, Moderate Hepatic Impairment
Interventions: Zanzalintinib; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Jun 21, 2025 · Synced May 21, 2026, 7:18 PM EDT

Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

NCT07036133

View directory record Official record

Conditions: Advanced Solid Tumors, Hematologic Malignancies
Interventions: Pralatrexate Injection; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Cerritos, California • Chicago, Illinois • Detroit, Michigan + 1 more

Source: ClinicalTrials.gov public record

Updated Feb 10, 2026 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

NCT02421042

View directory record Official record

Conditions: Hepatic Impairment, Hepatic Function
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated May 4, 2015 · Synced May 21, 2026, 7:18 PM EDT

Recruiting Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

NCT05660395

View directory record Official record

Conditions: Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Interventions: Loncastuximab Tesirine; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older

Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lynwood, California

Source: ClinicalTrials.gov public record

Updated Jul 15, 2025 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Hepatic Impairment Study

NCT00829231

View directory record Official record

Conditions: Liver Disease
Interventions: Sorafenib (Nexavar, BAY43-9006); Drug
Lead sponsor: Bayer; Industry
Eligibility: 50 Years to 75 Years

Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Knoxville, Tennessee

Source: ClinicalTrials.gov public record

Updated Nov 2, 2014 · Synced May 21, 2026, 7:18 PM EDT

Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

NCT04223635

View directory record Official record

Conditions: Moderate Hepatic Impairment
Interventions: Pexidartinib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jun 21, 2021 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

NCT01827657

View directory record Official record

Conditions: Hepatitis C
Interventions: GSK2336805; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 74 Years

Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated Jun 13, 2017 · Synced May 21, 2026, 7:18 PM EDT

Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

NCT07198087

View directory record Official record

Conditions: Primary Central Nervous System Lymphoma (PCNSL)
Interventions: Tirabrutinib; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Chandler, Arizona • Miami Lakes, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Apr 15, 2026 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

NCT05724693

View directory record Official record

Conditions: Healthy Volunteer, Hepatic Impairment
Interventions: Bemnifosbuvir (BEM); Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jul 30, 2024 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

NCT06535399

View directory record Official record

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: BMS-986369; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Chandler, Arizona • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Jan 22, 2026 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

NCT01916993

View directory record Official record

Conditions: Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
Interventions: NBI-98854 50 mg capsule; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 3
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota

Source: ClinicalTrials.gov public record

Updated Jan 15, 2014 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

NCT02412098

View directory record Official record

Conditions: Long QT Syndrome
Interventions: Eleclazine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated Jul 28, 2019 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

NCT05765344

View directory record Official record

Conditions: Hepatic Impairment, Healthy
Interventions: Bulevirtide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Lake Forest, California • Miami, Florida • Orlando, Florida + 1 more

Source: ClinicalTrials.gov public record

Updated Jan 25, 2026 · Synced May 21, 2026, 7:18 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

NCT05481411

View directory record Official record

Conditions: Hepatic Impairment
Interventions: Olpasiran; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Rialto, California • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Oct 14, 2025 · Synced May 21, 2026, 7:18 PM EDT